Human leukocyte antigen DR alpha inhibits renal cell carcinoma progression by promoting the polarization of M2 macrophages to M1 via the NF-κB pathway
Human leukocyte antigen DR alpha (HLA-DRA) is recognized for its inhibitory effect on the progression of clear cell renal cell carcinoma (ccRCC); high HLA-DRA expression levels are positively correlated with improved prognosis in patients with ccRCC. In this study, we evaluated HLA-DRA expression in ccRCCs, its effects on tumor-associated macrophage recruitment, and the influence of polarization. Clinical cohort analyses revealed that elevated HLA-DRA expression in ccRCC cells was correlated with enhanced tumor infiltration by M1-type macrophages. In addition, ccRCC prognosis was predicted by combining HLA-DRA expression level analysis and the M1/M2 macrophage ratio. In vitro studies demonstrated that ccRCC cells with increased HLA-DRA expression promoted THP-1 cell migration and induced macrophage polarization toward the M1 phenotype. The effect was further substantiated in a mouse xenograft model in which an increase in M1 macrophages was observed. In addition, co-culturing macrophages with the supernatant from cells overexpressing HLA-DRA induced the expression of proteins associated with both M1 and M2 macrophage polarization. HLA-DRA was intricately linked to the expression and secretion of chemokines, including CCL2, CCL5, MIP-1ɑ, and CXCL-10. Moreover, the NF-κB pathway activation promoted polarization to M1 macrophages. This study shows that HLA-DRA and the M1/M2 ratio are indicators of favorable prognosis in patients with ccRCC. HLA-DRA promotes M1-like polarization by regulating NF-κB, which can be used as a therapeutic target to enhance anti-tumor immunity.
Authors
- Haoxun Zhang (ORCID: https://orcid.org/0000-0002-8798-7711)
- Guoling Zhang (ORCID: https://orcid.org/0000-0002-2632-0577)
- Chunyang Wang (ORCID: https://orcid.org/0000-0003-2302-9933)
- Bowen Wang (ORCID: https://orcid.org/0009-0001-8145-8165)
- Yujie Liu (ORCID: https://orcid.org/0000-0001-7365-7896)
- Feng Xiong
- Yiwen Liu (ORCID: https://orcid.org/0000-0002-7982-7996)
Institutions
- Harbin Medical University (CN)
- Third Affiliated Hospital of Harbin Medical University (CN)
- First Affiliated Hospital of Harbin Medical University (CN)
Publication Details
- Journal
- International Immunopharmacology
- Published
- 2024-12-03
- DOI
- https://doi.org/10.1016/j.intimp.2024.113706
- Citations
- 9
- Primary Topic
- Immune cells in cancer
- Type
- article
- Field-Weighted Citation Impact
- 2.16